The multi-factorial nature of clinical multidrug resistance in cancer
Curative cancer therapy remains a major challenge particularly in cancers displaying
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a …
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a …
FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring …
I Solassol, F Pinguet, X Quantin - Biomolecules, 2019 - mdpi.com
Non-small-cell lung cancer (NSCLC) is the most common form of primary lung cancer. The
discovery of several oncogenic driver mutations in patients with NSCLC has allowed the …
discovery of several oncogenic driver mutations in patients with NSCLC has allowed the …
[HTML][HTML] Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
M Del Re, C Omarini, L Diodati, M Palleschi, I Meattini… - ESMO open, 2021 - Elsevier
Background Proton-pump-inhibitors (PPIs) are frequently prescribed for the management of
anticancer drug-related gastrointestinal symptoms. Palbociclib is a weak base with pH …
anticancer drug-related gastrointestinal symptoms. Palbociclib is a weak base with pH …
Proton pump inhibitors and oncologic treatment efficacy: a practical review of the literature for oncologists
AAT Uchiyama, PAIA Silva, MSM Lopes, CT Yen… - Current …, 2021 - mdpi.com
Proton pump inhibitors (PPIs) are the most commonly used anti-acid drugs worldwide,
including among cancer patients. However, drug-drug interactions between PPIs and other …
including among cancer patients. However, drug-drug interactions between PPIs and other …
Proton pump inhibitors and cancer: current state of play
Background: Proton pump inhibitors (PPIs) are one of the most widely used drugs worldwide
and are overprescribed in patients with cancer; there is increasing evidence of their effects …
and are overprescribed in patients with cancer; there is increasing evidence of their effects …
The association between proton pump inhibitor use and systemic anti‐tumour therapy on survival outcomes in patients with advanced non‐small cell lung cancer: A …
N Wei, B Zheng, W Que, J Zhang… - British Journal of Clinical …, 2022 - Wiley Online Library
Aims Proton pump inhibitors (PPIs) are often prescribed to prevent or treat gastrointestinal
disease. Whether the combination of systemic anti‐tumour therapy and PPIs leads to poor …
disease. Whether the combination of systemic anti‐tumour therapy and PPIs leads to poor …
Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer
ZY Xu, JL Li - OncoTargets and therapy, 2019 - Taylor & Francis
The development of small-molecule tyrosine kinase inhibitors (TKIs) that target the
epidermal growth factor receptor (EGFR) has revolutionized the management of non-small …
epidermal growth factor receptor (EGFR) has revolutionized the management of non-small …
Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study
Abstract Introduction Approximately 20–33% of all cancer patients are treated with acid-
reducing agents (ARAs), most commonly proton pump inhibitors (PPIs), to reduce …
reducing agents (ARAs), most commonly proton pump inhibitors (PPIs), to reduce …
The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer
The real-world efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …
Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment-a nationwide population-based study
YH Fang, YH Yang, MJ Hsieh, MS Hung… - Cancer management …, 2019 - Taylor & Francis
Purpose Concurrent proton pump inhibitor (PPI) use might reduce the plasma concentration
of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Clinically, the …
of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Clinically, the …